Karyopharm Therapeutics (NASDAQ: KPTI) has announced the appointment of Lori Macomber as executive vice president (EVP), chief financial officer (CFO), and treasurer, effective January 3, 2025.
Ms. Macomber, who will be responsible for leading and overseeing Karyopharm’s financial activities, brings more than 20 years of leadership experience in life science companies. Most recently, she served as CFO at Legend Biotech.
In a statement, Richard Paulson, president and CEO of Karyopharm, said, “Lori is an outstanding addition to the Karyopharm team. She brings extensive experience in strategic financial management and operations, which will be critical as we execute on our strategy to grow XPOVIO revenue and maintain our disciplined expense management as we progress our clinical pipeline.”
Ms. Macomber commented, “I am thrilled to join Karyopharm at this important stage as we advance our pipeline of novel therapies and look forward to working with the leadership team and contributing to the company’s success. I am impressed with both the team and the science, and I am excited to be a part of bringing much needed therapies to patients.
